Oncternal Therapeutics Inc (ONCT) Stock Analyst Ratings
USA - NASDAQ:ONCT - US68236P2065 - Common Stock
0.5266 USD
-0.17 (-24.11%)
0.61 USD
+0.08 (+15.84%)
ChartMill assigns a Buy % Consensus number of 43% to ONCT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.04. This target is 287.39% above the current price.
ONCT was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about ONCT.
In the last month the buy percentage fell by 37 points. So the trust of analysts is decreasing.
ONCT was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-09-12 | Brookline Capital | Downgrade | Buy -> Hold |
| 2024-09-12 | Northland Capital Markets | Downgrade | Outperform -> Market Perform |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-01-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-04 | Brookline Capital | Upgrade | Hold -> Buy |
| 2023-09-18 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-06-06 | HC Wainwright & Co. | Reiterate | Neutral |
| 2023-04-04 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-04-04 | Brookline Capital | Downgrade | Buy -> Hold |
| 2023-04-04 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2023-04-04 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-04-04 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-03-22 | Oppenheimer | Maintains | Outperform |
| 2023-03-14 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-12-22 | Cantor Fitzgerald | Initiate | Overweight |
| 2022-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-10 | Maxim Group | Initiate | Buy |
| 2022-02-24 | BTIG | Initiate | Buy |
| 2021-04-07 | Oppenheimer | Initiate | Outperform |
| 2021-03-30 | Brookline Capital | Initiate | Buy |
| 2021-03-12 | HC Wainwright & Co. | Maintains | Buy |
Oncternal Therapeutics Inc / ONCT FAQ
What is the average price target for Oncternal Therapeutics Inc (ONCT) stock?
6 analysts have analysed ONCT and the average price target is 2.04 USD. This implies a price increase of 287.39% is expected in the next year compared to the current price of 0.5266.
What is the consensus rating for Oncternal Therapeutics Inc (ONCT) stock?
The consensus rating for Oncternal Therapeutics Inc (ONCT) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.